Lipoprotein(a) and the atherosclerotic burden – Should we wait for clinical trial evidence before taking action?
The fact that lipoprotein(a) levels should be regarded as a causal residual risk factor in the atherosclerotic cardiovascular diseases (ASCVD) is now a no-brainer. This review article aims to summarize the latest evidence supporting the causal role of lipoprotein(a) in ASCVD and the potential strate...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2024-12-01
|
| Series: | Atherosclerosis Plus |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2667089524000452 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1846123276783321088 |
|---|---|
| author | Isabella Fichtner Chiara Macchi Alessandra Stefania Rizzuto Stefano Carugo Alberto Corsini Massimiliano Ruscica |
| author_facet | Isabella Fichtner Chiara Macchi Alessandra Stefania Rizzuto Stefano Carugo Alberto Corsini Massimiliano Ruscica |
| author_sort | Isabella Fichtner |
| collection | DOAJ |
| description | The fact that lipoprotein(a) levels should be regarded as a causal residual risk factor in the atherosclerotic cardiovascular diseases (ASCVD) is now a no-brainer. This review article aims to summarize the latest evidence supporting the causal role of lipoprotein(a) in ASCVD and the potential strategies to reduce the lipoprotein(a) burden until clinical trial results are available. Epidemiological and genetic data demonstrate the causal link between lipoprotein(a) and increased ASCVD risk. That being said, a specific question comes to mind: “must we wait for outcome trials in order to take action?”. Given that lipoprotein(a) levels predict incident ASCVD in both primary and secondary prevention contexts, with a linear risk gradient across its distribution, measuring lipoprotein(a) can unequivocally help identify patients who may later benefit from specific lipoprotein(a)-lowering therapies. This understanding has led various National Societies to recommend dosing lipoprotein(a) in high-risk individuals and to support the recommendation of measuring lipoprotein(a) levels at least once in every adult for risk stratification. |
| format | Article |
| id | doaj-art-93b4bfd1e23b4b35bb2cc5556d535adc |
| institution | Kabale University |
| issn | 2667-0895 |
| language | English |
| publishDate | 2024-12-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Atherosclerosis Plus |
| spelling | doaj-art-93b4bfd1e23b4b35bb2cc5556d535adc2024-12-14T06:33:27ZengElsevierAtherosclerosis Plus2667-08952024-12-01581623Lipoprotein(a) and the atherosclerotic burden – Should we wait for clinical trial evidence before taking action?Isabella Fichtner0Chiara Macchi1Alessandra Stefania Rizzuto2Stefano Carugo3Alberto Corsini4Massimiliano Ruscica5Department of Pharmacological and Biomolecular Sciences ''Rodolfo Paoletti'', Università Degli Studi Di Milano, Milan, ItalyDepartment of Pharmacological and Biomolecular Sciences ''Rodolfo Paoletti'', Università Degli Studi Di Milano, Milan, ItalyDepartment of Clinical Sciences and Community Health, Università Degli Studi Di Milano, Milan, ItalyDepartment of Clinical Sciences and Community Health, Università Degli Studi Di Milano, Milan, Italy; Department of Cardio-Thoracic-Vascular Diseases, Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, ItalyDepartment of Pharmacological and Biomolecular Sciences ''Rodolfo Paoletti'', Università Degli Studi Di Milano, Milan, ItalyDepartment of Pharmacological and Biomolecular Sciences ''Rodolfo Paoletti'', Università Degli Studi Di Milano, Milan, Italy; Department of Cardio-Thoracic-Vascular Diseases, Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy; Corresponding author. Department of Pharmacological and Biomolecular Sciences ''Rodolfo Paoletti'', Università Degli Studi Di Milano, Milan, Italy.The fact that lipoprotein(a) levels should be regarded as a causal residual risk factor in the atherosclerotic cardiovascular diseases (ASCVD) is now a no-brainer. This review article aims to summarize the latest evidence supporting the causal role of lipoprotein(a) in ASCVD and the potential strategies to reduce the lipoprotein(a) burden until clinical trial results are available. Epidemiological and genetic data demonstrate the causal link between lipoprotein(a) and increased ASCVD risk. That being said, a specific question comes to mind: “must we wait for outcome trials in order to take action?”. Given that lipoprotein(a) levels predict incident ASCVD in both primary and secondary prevention contexts, with a linear risk gradient across its distribution, measuring lipoprotein(a) can unequivocally help identify patients who may later benefit from specific lipoprotein(a)-lowering therapies. This understanding has led various National Societies to recommend dosing lipoprotein(a) in high-risk individuals and to support the recommendation of measuring lipoprotein(a) levels at least once in every adult for risk stratification.http://www.sciencedirect.com/science/article/pii/S2667089524000452Lipoprotein(a)Atherosclerotic cardiovascular risklipoprotein(a) measurements |
| spellingShingle | Isabella Fichtner Chiara Macchi Alessandra Stefania Rizzuto Stefano Carugo Alberto Corsini Massimiliano Ruscica Lipoprotein(a) and the atherosclerotic burden – Should we wait for clinical trial evidence before taking action? Atherosclerosis Plus Lipoprotein(a) Atherosclerotic cardiovascular risk lipoprotein(a) measurements |
| title | Lipoprotein(a) and the atherosclerotic burden – Should we wait for clinical trial evidence before taking action? |
| title_full | Lipoprotein(a) and the atherosclerotic burden – Should we wait for clinical trial evidence before taking action? |
| title_fullStr | Lipoprotein(a) and the atherosclerotic burden – Should we wait for clinical trial evidence before taking action? |
| title_full_unstemmed | Lipoprotein(a) and the atherosclerotic burden – Should we wait for clinical trial evidence before taking action? |
| title_short | Lipoprotein(a) and the atherosclerotic burden – Should we wait for clinical trial evidence before taking action? |
| title_sort | lipoprotein a and the atherosclerotic burden should we wait for clinical trial evidence before taking action |
| topic | Lipoprotein(a) Atherosclerotic cardiovascular risk lipoprotein(a) measurements |
| url | http://www.sciencedirect.com/science/article/pii/S2667089524000452 |
| work_keys_str_mv | AT isabellafichtner lipoproteinaandtheatheroscleroticburdenshouldwewaitforclinicaltrialevidencebeforetakingaction AT chiaramacchi lipoproteinaandtheatheroscleroticburdenshouldwewaitforclinicaltrialevidencebeforetakingaction AT alessandrastefaniarizzuto lipoproteinaandtheatheroscleroticburdenshouldwewaitforclinicaltrialevidencebeforetakingaction AT stefanocarugo lipoproteinaandtheatheroscleroticburdenshouldwewaitforclinicaltrialevidencebeforetakingaction AT albertocorsini lipoproteinaandtheatheroscleroticburdenshouldwewaitforclinicaltrialevidencebeforetakingaction AT massimilianoruscica lipoproteinaandtheatheroscleroticburdenshouldwewaitforclinicaltrialevidencebeforetakingaction |